Quadruple HCV therapy effective for nonresponders
from The Clinical Advisor
Two direct-acting antivirals against hepatitis C virus (HCV) currently in development improved virologic responses among patients with HCV when administered alone or in combination with pegylated interferon-alpha-2a (pegIFN-alpha-2a) and ribavirin, phase-2 trial results indicate.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063